

Review Article

Evaluating Saliva as a Diagnostic Tool for COVID-19 in Dental Settings: A Meta-Analysis of Saliva, Nasopharyngeal, and Serum Specimens

Katherine Sagredo-Olivares¹, Constanza Morales-Gómez¹, Juan Aitken-Saavedra^{2-4*}

¹Undergraduate, Faculty of Dentistry, University of Chile, Santiago, Chile.

²Department of Oral Pathology and Medicine, Faculty of Dentistry, University of Chile, Santiago, Chile.

³Graduate Program in Dentistry, School of Dentistry, Federal University of Pelotas, Pelotas, Brazil.

⁴Dental Service, San Camilo Hospital, San Felipe, Chile Correspondence: Postal address: 8380492 Olivos 943, Independencia, Santiago, Chile.

*E-mail ✉ jaitken@odontologia.uchile.cl

Received: 03 June 2023; Revised: 06 September 2023; Accepted: 11 September 2023

ABSTRACT

COVID-19 testing uses different types of specimens, including nasopharyngeal swabs, saliva, and serum. While the nasopharyngeal swab (NPS) remains the gold standard for diagnosing COVID-19, its invasive nature can cause patient discomfort and requires trained personnel for sample collection. This study aimed to evaluate the effectiveness of nasopharyngeal, serum specimens, and saliva in detecting COVID-19 and to compare saliva with the other two methods. A systematic search was conducted following the PRISMA 2020 guidelines across PubMed, the Cochrane COVID-19 study register, and the Saudi Digital Library. The QUADAS-2 tool was used to assess study quality. The primary outcome measured the sensitivity and specificity of serum, saliva, and NPS, while the secondary outcome focused on comparing the diagnostic accuracy of saliva versus NPS and serum. Data were collected from 39 studies in 20 countries, analyzing 20,024 patients and 22,123 samples. Despite significant heterogeneity ($P < 0.001$), the meta-analysis revealed significant differences in sensitivity among all specimen types, especially between NPS and saliva. The area under the curve (AUC) values indicated a high diagnostic performance: serum (AUC = 1.00) showed the highest efficacy, followed by saliva (AUC = 0.97) and NPS (AUC = 0.94). These findings suggest that saliva presents a viable, non-invasive alternative for the diagnosis of COVID-19 with comparable reliability to NPS.

Keywords: COVID-19 nucleic acid testing, Nasopharyngeal, COVID-19 testing, COVID-19 serological testing, Saliva, Serum

How to Cite This Article: Sagredo-Olivares K, Morales-Gómez C, Aitken-Saavedra J. Evaluating Saliva as a Diagnostic Tool for COVID-19 in Dental Settings: A Meta-Analysis of Saliva, Nasopharyngeal, and Serum Specimens. Turk J Dent Hyg. 2023;3:34-50. <https://doi.org/10.51847/otSbO5MoJp>

Introduction

COVID-19 is an infectious disease caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was found in Wuhan first, China, in December 2019 and has since led to a global health crisis [1, 2]. On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic, and the virus continues to spread

worldwide, with reports of second and potential third waves [1-3]. As of February 21, 2023, WHO has recorded 757,264,511 confirmed cases and 6,850,594 fatalities due to COVID-19 [4].

The virus primarily spreads through respiratory and salivary droplets, as well as direct contact with infected individuals. Aerosol transmission and fecal-oral routes have also been identified, along with indirect spread via fomites and surfaces [1, 3, 5-10].

Although nasopharyngeal swabs (NPS) remain the gold standard for COVID-19 diagnosis, proper sample collection requires trained professionals, making it resource-intensive and costly for healthcare systems. Furthermore, NPS collection is contraindicated for individuals with anticoagulant therapy, coagulopathy, or significant nasal septum deviation, limiting its widespread applicability [11]. Given these challenges, an alternative diagnostic method that is less invasive, cost-effective, and reduces exposure risks for healthcare workers is highly desirable [12-16].

Since antibodies' presence against SARS-CoV-2 has been found in the mouth, saliva-based testing has the potential to serve as a different sampling method for COVID-19 detection. In addition to being non-invasive, saliva testing offers a rapid and convenient approach to diagnosing the virus [17]. Several studies have investigated the diagnostic accuracy of saliva in comparison with serum-based tests and nasopharyngeal tests for COVID-19 detection [1, 5, 16]. It is essential to assess the overall effectiveness of these different testing methods, particularly in dental settings, where infection prevention and early detection are critical [18, 19]. The objective of this study was to compare the diagnostic performance of nasopharyngeal, serum specimens, and saliva in detecting COVID-19 and to determine the most efficient and patient-friendly testing method. Therefore, this systematic review focuses on evaluating the diagnostic reliability of saliva-based tests in contrast to nasopharyngeal swabs and serum-based testing for the identification of SARS-CoV-2.

Materials and Methods

This study was formally registered, and approval was obtained from the ethical committee to proceed with the research.

PICO-based research question

The primary focus of this study was to determine whether saliva-based diagnostic tests are comparable serum-based to nasopharyngeal tests for COVID-19 detection.

PICO framework for the study

Population: Individuals who were screened, suspected, or confirmed to have COVID-19.

Intervention: Diagnostic testing for COVID-19 using saliva, nasopharyngeal, and serum specimens.

Comparator/Control: Reverse transcription polymerase chain reaction (RT-PCR) validation tests.

Outcome: Evaluation of sensitivity and specificity for each specimen type, including saliva, nasopharyngeal, and serum samples.

Data extraction

Relevant data were extracted from three major databases: Saudi Digital Library, PubMed, and the Cochrane COVID-19 study register. The search was conducted using specific filters and keywords such as "COVID-19," "SARS-CoV-2," "saliva," "nasopharyngeal," "serum," and "COVID-19 testing." This systematic review followed the PRISMA 2020 guidelines ensuring a structured approach to data collection. The selected studies and registers covered research published between January 2020 and June 2021 (Figure 1).




Figure 1. The PRISMA 2020 flow diagram, outlines the process of data search, screening, eligibility assessment, and final inclusion of studies for the systematic review and meta-analysis; this diagram integrates information from multiple databases and study registers to ensure a structured and transparent selection of relevant research

Eligibility criteria

Studies were selected based on specific inclusion and exclusion criteria. Articles that were duplicates, unrelated to the topic, written in languages other than English, or categorized as surveys, abstracts, case reports, systematic reviews, reviews, or meta-analyses were excluded. In contrast, studies that explicitly examined saliva, nasopharyngeal, and serum specimens from individuals who were screened, suspected, or diagnosed with SARS-CoV-2 were included. Only full-text articles published in English were considered, while studies with sample sizes below 50, those derived from other research, mixed-method studies incorporating questionnaires or reviews, and those with insufficient data were excluded.

Primary and secondary outcomes

The primary objective of this study was to evaluate the diagnostic accuracy of saliva, serum, and nasopharyngeal specimens by measuring their sensitivity and specificity. The secondary aim was to compare the diagnostic performance of saliva against nasopharyngeal and serum specimens in detecting COVID-19.

Risk of bias assessment

To assess the quality and reliability of the included studies, the QUADAS-2 tool [20, 21] was employed, which evaluates both the risk of bias and applicability concerns. Investigators were trained and calibrated by experienced specialist dentists familiar with similar research projects. Any discrepancies among the reviewers were resolved through mutual discussion until a consensus was reached [20].

Study parameters

- *Participants:* Individuals, either symptomatic or asymptomatic, screened for, suspected of, or diagnosed with COVID-19.
- *Index tests:* Diagnostic evaluation using saliva, nasopharyngeal, or serum specimens.

- *Target condition:* Identification of SARS-CoV-2 infection.
- *Reference standard:* RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) nucleic acid assay.

Bias and applicability concerns

All four domains of risk of bias and three domains of applicability concerns were assessed using tailored questions to ensure a comprehensive evaluation. A study was classified as having a low risk of bias (green) if all signaling questions were answered “yes.” If any question was answered “no,” indicating a potential source of bias, it was categorized as a high risk of bias (red). If the available data were insufficient to determine the level of bias, the study was marked as unclear risk of bias (yellow). Similarly, applicability concerns were rated as low, high, or unclear, following the same classification approach.

Results and Discussion

Following the PRISMA 2020 guidelines (**Figure 1**), a total of 1,283 articles initially were identified. Among these, 1,120 were sourced from PubMed, 39 from the Saudi Digital Library (SDL), and 124 from the Cochrane COVID-19 study register. After removing 29 duplicate articles, 781 studies that were unrelated to COVID-19 testing or the specimen types under experiment were excluded. Additionally, 279 articles that met the exclusion criteria—such as non-English publications, abstracts, case reports, reviews, and systematic reviews or meta-analyses—were also removed.

A total of 194 articles underwent a detailed eligibility screening. Based on the inclusion criteria, 39 studies were selected for quality assessment, while 6 studies qualified for quantitative synthesis. The entire selection process is illustrated in **Figure 2**.

SALIVA STUDIES		RISK OF BIAS				APPLICABILITY CONCERNS		
Sl. No	Study details	Patient selection	Index Test	Reference Standard	Flow and Timing	Patient selection	Index Test	Reference Standard
1	Procop, G. W., et al (2020).	😊	😊	😊	😊	😊	😊	😊
2	Pasomsub, E., et al (2021).	😊	😊	😞	😊	😊	😊	😊
3	Altawalah, H., et al (2020).	😊	😊	😊	😊	😊	😊	😊
4	Babady N.E.,et al (2021).	😞	😊	😊	😊	😊	😊	😊
5	Nagura-Ikeda, M., et al (2020).	😊	😞	😊	😊	😊	😊	😊
6	Rao, M., et al (2021).	😊	😊	😊	😊	😊	😊	😊
7	Vaz, S. N., (2020).	😊	😊	😊	😞	😊	😊	😊
8	Griesemer, S. B., et al (2021).	😊	😊	😊	😊	😊	😊	😊
9	Herrera, L. A,et al (2021).	😞	😊	😞	😊	😞	😊	😊
10	Manabe, Y. C.,et al (2020).	😊	😊	😞	😊	😞	😊	😊
11	Jamal, A. J., et al (2021).	😊	😊	😊	😊	😞	😞	😊
12	Braz-Silva, P. H., et al (2020).	😊	😊	😊	😊	😞	😊	😊
13	Plantamura, J.,et al (2021). et al	😊	😊	😞	😞	😊	😊	😊
14	Amendola, A., et al (2021).	😊	😞	😊	😊	😊	😞	😊
15	Senok, A, et al (2020).	😊	😊	😊	😊	😊	😊	😊
16	Sutjipto, S., et al (2020).	😞	😞	😊	😊	😊	😊	😊
17	Jamal, A. J.,et al (2020).	😞	😊	😊	😊	😊	😊	😊
18	Sun, Q.,et al (2021).	😊	😊	😊	😊	😊	😊	😊
19	Ana Laura, G. O., et al (2021).	😊	😊	😊	😊	😊	😊	😞
20	Pisanic, N., et al (2020).	😊	😊	😊	😊	😊	😊	😊
21	Isho B et al (2020)	😞	😊	😞	😞	😊	😊	😞

a)

NASOPHARYNGEAL STUDIES		RISK OF BIAS				APPLICABILITY CONCERNS		
Sl. No	Study details	Patient selection	Index Test	Reference Standard	Flow and Timing	Patient selection	Index Test	Reference Standard
1	Rao, M., et al (2021).	😊	😊	😊	😊	😊	😊	😊
2	Jamal, A. J., et al (2021).	😊	😊	😊	😊	😞	😞	😊
3	Braz-Silva, P. H., et al (2020).	😊	😊	😊	😊	😞	😊	😊
4	Hirotsu, Y., et al . (2020).	😞	😞	😊	😊	😊	😞	😊
5	Toptan, T., et al (2021).	😊	😊	😊	😊	😞	😊	😊
6	Sutjipto, S., et al (2020).	😞	😞	😊	😊	😊	😊	😊
7	Jamal, A. J.,et al (2020).	😞	😊	😊	😊	😊	😊	😊
8	Sun, Q.,et al (2021).	😊	😊	😊	😊	😊	😊	😊

b)

SERUM STUDIES		RISK OF BIAS				APPLICABILITY CONCERNS		
Sl. No	Study details	Patient selection	Index Test	Reference Standard	Flow and Timing	Patient selection	Index Test	Reference Standard
1	Pisanic, N., et al (2020).	😊	😊	😊	😊	😊	😊	😊
2	Isho B et al (2020)	😊	😊	😊	😊	😊	😊	😊
3	Plebani, M.,et al (2021).	😊	😊	😊	😊	😊	😊	😊
4	Chansaenroj, J., et al (2021).	😊	😊	😊	😊	😊	😊	😊
5	Wu, J. L., et al. (2020).	😊	😊	😊	😊	😊	😊	😊
6	Kim, D., et al (2021).	😊	😊	😊	😊	😊	😊	😊
7	Edouard, S., et al (2021).	😊	😊	😊	😊	😊	😊	😊
8	Dou, X., et al (2021).	😊	😊	😊	😊	😊	😊	😊
9	Van Elslande, J., et al (2020).	😊	😊	😊	😊	😊	😊	😊
10	Pérez-García, et al (2020).	😊	😊	😊	😊	😊	😊	😊
11	Iruzubieta, P., et al (2021).	😊	😊	😊	😊	😊	😊	😊

c)


Figure 2. (a, b, and c): The quality assessment results of the studies using the QUADAS 2 tool for saliva (a), nasopharyngeal (b), and serum (c) specimens; the yellow color indicates an unclear risk of bias or applicability concern, red signifies a high risk of bias and applicability concern, and green represents a low risk of bias and applicability concern.

In this systematic review, 39 studies were included, covering twenty countries, 20,024 patients, and 22,123 samples. Further analysis was carried out on 33 studies that provided specific data on sensitivity and specificity for the specimens examined. The results of the sensitivity and specificity for serum specimens saliva and nasopharyngeal in the meta-analysis are displayed in the forest plots in **Figure 3**. **Table 1** demonstrates the evaluation of base data. **Table 2** provides an overview of the performance of the three specimen types under evaluation.

The positive likelihood ratio (PLR) for all specimens was greater than 1, indicating a higher probability of COVID-19 diagnosis in patients with positive test results. For saliva, the PLR was found to be 32.0 [14.0, 73.2], suggesting that individuals with a positive saliva

test are 32 times more likely to test positive for the virus compared to healthy individuals. The negative likelihood ratio (NLR) for all tests was less than 1, meaning patients with negative results have a reduced likelihood of being infected. The NLR indicates that a lower percentage of true COVID-19 cases tested negative compared to those who tested negative and were not infected. Serum samples showed the lowest NLR, meaning they are the least likely to provide false negative results, making them the most reliable in this regard. The diagnostic odds ratio (DOR), which compares the likelihood of a positive result to a negative result, was highest for serum testing. This suggests that serum tests, particularly for active infections detected by IgG, offer the most effective method for COVID-19 diagnosis.





c)

Figure 3. Forest plots for the saliva studies (a), nasopharyngeal (NPS) studies (b), and serum studies (c)

Table 1. Statistical base data of studies

Study	TP	FP	FN	TN	Total
Saliva					
Altawalrah <i>et al.</i> [22]	305	17	61	508	891
Amendola <i>et al.</i> [23]	36	3	31	99	169
Ana Laura <i>et al.</i> [24]	14	6	3	133	156
Babady <i>et al.</i> [25]	16	1	1	69	87
Braz-Silva <i>et al.</i> [26]	55	10	15	121	201
Griesemer <i>et al.</i> [27]	91	10	14	348	463
Herrera <i>et al.</i> [28]	139	10	34	1867	2050
Jamal <i>et al.</i> [29]	44	8	20	19	91
Jamal <i>et al.</i> [30]	46	9	18	15	88
Manabe <i>et al.</i> [31]	18	2	11	8	39
Pasomsub <i>et al.</i> [32]	16	2	3	179	200
Plantamura <i>et al.</i> [33]	180	29	25	971	1205
Procop <i>et al.</i> [34]	38	1	0	177	216
Rao <i>et al.</i> [35]	62	1	3	496	562
Senok <i>et al.</i> [36]	19	9	7	366	401
Sun <i>et al.</i> [37]	84	0	1	90	175
Sutjipto <i>et al.</i> [38]	31	2	52	19	104
Vaz <i>et al.</i> [39]	67	2	4	82	155
NPS					
Braz-Silva <i>et al.</i> [26]	52	15	18	131	216
Hirotsu <i>et al.</i> [40]	32	1	26	254	313
Jamal <i>et al.</i> [29]	44	23	5	19	91
Jamal <i>et al.</i> [30]	46	18	9	15	88
Rao <i>et al.</i> [35]	47	3	18	494	562

Sun <i>et al.</i> [37]	84	1	0	90	175
Sutjipto <i>et al.</i> [38]	62	0	11	32	105
Toptan <i>et al.</i> [41]	45	0	13	9	67
Serum					
Chansaenroj <i>et al.</i> [42]	187	19	5	164	375
Dou <i>et al.</i> [43]	57	4	3	141	205
Kim <i>et al.</i> [44]	127	0	3	100	230
Pérez-García <i>et al.</i> [45]	58	0	32	161	251
Plebani <i>et al.</i> [46]	4	4	1	207	216
Van Elslande <i>et al.</i> [47]	261	4	0	99	364
Wu <i>et al.</i> [48]	74	0	0	74	148

Table 2. Summary

Parameter	Saliva	NPS	Serum
Sensitivity	0.84 [0.75, 0.91]	0.84 [0.70, 0.92]	0.97 [0.88, 1.00]
Specificity	0.97 [0.94, 0.99]	0.97 [0.82, 1.00]	0.99 [0.95, 1.00]
Positive likelihood ratio	32.0 [14.0, 73.2]	28.0 [4.2, 189.4]	72.2 [18.2, 287.4]
Negative likelihood ratio	0.16 [0.10, 0.26]	0.17 [0.09, 0.32]	0.03 [0.01, 0.13]
Diagnostic odds ratio	199 [58, 687]	168 [22, 1281]	2827 [410, 19476]

The variability observed between the three specimen types—saliva, nasopharyngeal swabs (NPS), and serum—is highlighted by the statistical heterogeneity in the outcomes. **Table 3** presents the results of this variability. The null hypothesis assumes that all studies show consistent outcomes for COVID-19 detection, specifically for the identification of SARS-CoV-2. If the P-value from the chi-square test is greater than 0.1 ($P > 0.1$), it would support the null hypothesis. But, as

indicated in **Table 3**, a P-value of less than 0.0001 ($P < 0.0001$) points to significant heterogeneity across the outcomes of the COVID-19 tests. The inconsistency index (I²), which measures heterogeneity, is over 50%, confirming the presence of substantial variability. As shown in **Table 3**, the heterogeneity across the studies varies significantly, with an I² range of 96% to 99%, all with statistically significant P-values.

Table 3. Heterogeneity statistics for the performance of saliva, NPS, and serum specimens for COVID-19 testing; NPS = nasopharyngeal swab

Parameter	Measure	Saliva	NPS	Serum
Heterogeneity	Q	44.639	153.041	70.838
	df	2.00	2.00	2.00
	P(x ²)	< 0.0001	< 0.0001	< 0.0001
Inconsistency	I ² [95%CI]	96 [92 - 99]	99 [98 - 99]	97 [95 - 99]

Fagan plots were used to assess how the diagnostic results from saliva, NPS, and serum samples affected the likelihood of a patient having COVID-19. Starting with an initial 25% probability of infection, the results indicated a significant increase in this probability to 91%, 90%, and 96% for saliva, NPS, and serum samples, respectively, when the test results were positive. Conversely, when the test results were negative, the probability of COVID-19 dropped from 25% to 5%, 5%, and 1% for saliva, NPS, and serum samples, respectively.

The summary receiver operating characteristic (SROC) curve, shown in **Figure 4**, demonstrates the pooled sensitivity of the three diagnostic tests. The ROC curve

represents the likelihood of each specimen type detecting COVID-19, while the area under the curve (AUC) measures how well these tests can differentiate between positive and negative cases. The SROC-AUC model helps in comparing the diagnostic capability of each specimen for COVID-19 detection. The pooled sensitivity for saliva tests was found to be 0.84 (95% CI, 0.75 to 0.91), indicating a strong ability to identify positive SARS-CoV-2 cases. Additionally, the pooled specificity for saliva was 0.97 (95% CI, 0.94 to 0.99), reflecting the test's high accuracy in identifying COVID-19-negative patients. The AUC for saliva was 0.97 (95% CI, 0.95 to 0.98), highlighting the excellent performance of saliva tests in detecting the virus.




Figure 4. Summary receiver operating characteristic (SROC) curve; area under the curve (AUC) for saliva (a), NPS (b), and serum (c).

The analysis showed that NPS tests had a pooled sensitivity of 0.84 (95% CI, 0.70 to 0.92), indicating a strong ability to identify true positive SARS-CoV-2 cases. The specificity was 0.97 (95% CI, 0.82 to 1.00), suggesting it effectively distinguishes COVID-19-negative patients. The AUC value for NPS was 0.94 (95% CI, 0.92 to 0.96), signifying that NPS tests are highly reliable for detecting the virus.

Serum tests performed even better, with a pooled sensitivity of 0.97 (95% CI, 0.88 to 1.00), indicating excellent performance in detecting SARS-CoV-2. The pooled specificity was 0.99 (95% CI, 0.99 to 1.00),

showing that it has an exceptional capacity to identify negative cases. The AUC for serum was 1.00 (95% CI, 0.95 to 0.98), highlighting its superior ability to detect the virus.

When comparing the three specimen types, serum samples exhibited the highest detection performance with a sensitivity of 0.97 (95% CI, 0.88 to 1.00), followed by saliva samples (0.84, 95% CI, 0.75 to 0.91) and NPS (0.84, 95% CI, 0.70 to 0.92). Serum also had the highest specificity estimate of 0.99 (95% CI, 0.95 to 1.00). However, it should be noted that the serum samples came from individuals suspected of or diagnosed with active COVID-19 infection. Importantly, none of the studies examined IgM, IgA, or IgG levels, with the focus being on IgG, which displayed the highest specificity, sensitivity, and overall detection performance.

The meta-analysis and systematic review aimed to assess the effectiveness of saliva-based COVID-19 testing for screening or remote testing, an option that doesn't require healthcare professionals for specimen collection. Saliva is a sample commonly handled by dental practitioners in their daily work, making its diagnostic accuracy particularly relevant for them. The analysis compared the diagnostic performance of three frequently used specimen types: saliva, nasopharyngeal swab (NPS), and serum.

NPS, a respiratory specimen, is widely recognized as the gold standard for SARS-CoV-2 detection and has been extensively used in COVID-19 testing and retesting [22, 23, 26, 29-32, 34-38, 40, 41, 49, 50]. However, studies focusing exclusively on NPS samples were less common [40, 41, 50-52]. There are several reasons why NPS, despite being the preferred choice, has some limitations. One issue is the variation in viral load at different stages of infection, which may result in lower viral loads during later stages, potentially leading to false-negative results [53]. Additionally, the test's reliability can be influenced by sample quality, which in turn depends on how well the patient follows collection instructions. Incorrect specimen collection techniques can also contribute to false negatives. Furthermore, research has shown that NPS testing conducted by trained professionals in hospital settings tends to yield more reliable results than tests conducted on outpatients or suspected cases [52]. NPS collection is also less well-tolerated by pediatric patients, though it remains recommended for those who are at higher risk, such as those with close contacts, epidemiological factors like infection clusters, or hospitalization requirements [54-60]. Complications, such as nasal bleeding, pain, or dislodgement of the swab have been reported with NPS

testing, some of which required medical interventions to resolve [61-67].

Serum samples can be analyzed for the presence of various immunoglobulins (Ig), including IgA, IgG, and IgM, which can be evaluated during different stages of infection and compared with other specimen types. These findings were cross-referenced with RT-PCR analysis, serving as the confirmatory test. Our study revealed that IgG exhibited higher specificity in symptomatic COVID-19 patients compared to those who were asymptomatic, and it provided more reliable results during active infection [42-48, 68-71]. This can be attributed to the seroconversion period, where severe cases of SARS-CoV-2 infection tend to show earlier seroconversion, leading to the development of elevated IgG levels, as compared to patients with mild symptoms. In some instances, measurable IgG antibodies might not be detectable, but the presence of neutralizing antibodies could indicate immunity [72, 73]. Variations in the frequency and timing of serum sample collection, as well as uncertainty regarding the precise onset of IgG response during seroconversion, may introduce confounding factors in the analysis. Although IgG levels can be a useful aid in assessing the status of active COVID-19 infection [74], serological tests with insufficient sensitivity and specificity are not recommended for confirming COVID-19 diagnosis [42-48, 68-73, 75-77]. Additionally, many studies lacked standardized methodologies for analyzing serological specimens, which could have led to over- or underestimation of the findings.

Saliva presents itself as a promising specimen for COVID-19 detection for several reasons. It contains epithelial cells from the oral cavity, which possess numerous angiotensin-converting enzyme 2 (ACE2) receptors. ACE2 is essential for SARS-CoV-2 entry into host cells, making saliva an ideal specimen for detecting the virus. For dental professionals, saliva is the most accessible sample for screening or diagnosing patients, as well as healthcare workers within or outside clinical settings [78]. Given that dental practice involves handling saliva, there is an unavoidable risk of SARS-CoV-2 transmission, both directly and indirectly. Therefore, dentists should take the necessary precautions to prevent contamination [26, 79, 80]. Saliva's ease of access makes it particularly advantageous in dental practice, where both asymptomatic and symptomatic COVID-19 patients pose a high risk of exposure. Access to saliva-based testing can help mitigate the spread of SARS-CoV-2 in dental environments.

SARS-CoV-2 can be present in saliva through three primary routes: (1) liquid droplets originating from

both the upper and lower respiratory tracts, (2) gingival crevicular fluid derived from SARS-CoV-2-infected blood, and (3) salivary glands and their ducts [80, 81]. Studies have shown that ACE2 inhibitor levels in COVID-19 patients are higher in minor salivary glands compared to the lungs, which may explain why SARS-CoV-2 can be detected in asymptomatic individuals before any lung involvement is evident on radiologic imaging, further suggesting saliva as a possible source of viral transmission [82]. Detection of COVID-19 has been reported in both asymptomatic and symptomatic individuals [83-89]. Most studies collect saliva using one of three methods: saliva swabs, coughing up saliva, or directly from the salivary gland ducts [90]. However, our study found that the collection techniques were not standardized, which could potentially influence the results of the studies. It was identified that viral load in saliva fluctuated over time, with peak levels occurring early in the onset of symptoms, followed by a decline in viral load [72, 91]. Saliva presents a promising alternative to nasopharyngeal swabs (NPS) for COVID-19 testing, as NPS collection can be uncomfortable for patients and carries a risk of complications [92]. The need for trained professionals, personal protective equipment, and transportation of sample collection kits adds a logistical and financial burden, potentially hindering a country's economic growth. The use of self-collected saliva for large-scale screening, when proper collection methods are employed, could offer a practical solution to these challenges. False-negative results from NPS tests, even when administered by trained personnel, have highlighted the need for standardized procedures, calibration, and monitoring of the NPS technique. Such discrepancies have led to retesting, particularly when patients show symptoms indicative of COVID-19 [14, 93].

As the demand for COVID-19 testing and retesting continues to rise, alongside global regulations for quarantine, travel, and screening, saliva specimens have emerged as a convenient, non-invasive alternative for testing. Saliva collection presents no procedural discomfort, is suitable for both children and adults, has no contraindications for medically compromised patients, and yields comparable results to nasopharyngeal swabs (NPS). Many studies support the use of saliva for COVID-19 diagnosis, supporting its potential as an effective and user-friendly option [7, 14, 26, 72, 79, 83-91, 93-105].

Despite the huge volume of data available for saliva and NPS specimens, the study had certain limitations. A major challenge was the lack of standardized methodologies for data collection and statistical

analysis, making it difficult to retrieve consistent baseline data for performance evaluation. Multiple testing techniques were used, and variations in these methods influenced the outcomes, even though findings were confirmed with RT-PCR at different time points. The findings from the three specimens—saliva, NPS, and serum—are generally applicable, but the results from serum specimens should be interpreted with caution due to insufficient study data, particularly regarding the assessment of immunoglobulin levels during early and active stages of infection. Despite significant heterogeneity ($P < 0.001$), saliva specimens were found to have strong diagnostic efficacy for detecting COVID-19 and can be considered a reliable alternative for COVID-19 testing.

Conclusion

In conclusion, our review and meta-analysis demonstrate that saliva is a reliable specimen for detecting COVID-19, with results comparable to the gold standard nasopharyngeal swabs (NPS). NPS specimens, however, would be collected with care by trained professionals to minimize complications and ensure accurate diagnosis. Serum specimens, specifically for SARS-CoV-2 IgG, are effective in detecting active COVID-19 in symptomatic patients but would not be used as the sole diagnostic tool. Saliva collection is non-invasive, easy to perform, and does not require professional training, leading to higher patient acceptance and making it safe for use in children. Self-administration of saliva tests can be conducted at home or in healthcare settings, making it particularly advantageous for the elderly, medically compromised individuals, and those on anticoagulants. These tests hold promise as point-of-care diagnostics and can be easily used by dental healthcare providers, allowing for convenient COVID-19 screening without the need for referrals. Saliva-based testing also has great potential for widespread use in business, social, educational, and entertainment settings as we move toward a post-pandemic normal. Future research should focus on standardizing collection techniques, identifying the most effective saliva collection method for COVID-19 testing, and evaluating its diagnostic reliability for point-of-care use.

Acknowledgments: None

Conflict of Interest: None

Financial Support: None

Ethics Statement: None

References

1. Chu AW, Yip CC, Chan WM, Ng AC, Chan DL, Siu RH, et al. Evaluation of an automated high-throughput liquid-based RNA extraction platform on pooled nasopharyngeal or saliva specimens for SARS-CoV-2 RT-PCR. *Viruses*. 2021;13(4):615. doi:10.3390/v13040615
2. Dos Santos WG. Natural history of COVID-19 and current knowledge on treatment therapeutic options. *Biomed Pharmacother*. 2020;129:110493. doi:10.1016/j.biopha.2020.110493
3. World Health Organization. WHO Coronavirus (COVID-19) dashboard. Available from: WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [accessed 2023 February 24th]. Available from: <https://covid19.who.int/>
4. Huang N, Pérez P, Kato T, Mikami Y, Okuda K, Gilmore RC, et al. SARS-CoV-2 infection of the oral cavity and saliva. *Nat Med*. 2021;27(5):892-903. doi:10.1038/s41591-021-01296-8
5. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ*. 2020;370:m2516. doi:10.1136/bmj.m2516
6. Böger B, Fachi MM, Vilhena RO, Cobre AF, Tonin FS, Pontarolo R. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. *Am J Infect Control*. 2021;49(1):21-9. doi:10.1016/j.ajic.2020.07.011
7. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy Á, et al. Saliva as a candidate for COVID-19 diagnostic testing: a meta-analysis. *Front Med (Lausanne)*. 2020;7:465. doi:10.3389/fmed.2020.00465
8. Elshazli RM, Toraih EA, Elgaml A, El-Mowafy M, El-Mesery M, Amin MN, et al. Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: a meta-analysis of 6320 patients. *PLoS One*. 2020;15(8):e0238160. doi:10.1371/journal.pone.0238160
9. Mohammadi A, Esmailzadeh E, Li Y, Bosch RJ, Li JZ. SARS-CoV-2 detection in different respiratory sites: a systematic review and meta-analysis. *EBioMedicine*. 2020;59:102903. doi:10.1016/j.ebiom.2020.102903
10. Shirazi S, Stanford CM, Cooper LF. Characteristics and detection rate of SARS-CoV-2 in alternative sites and specimens pertaining to

- dental practice: an evidence summary. *J Clin Med.* 2021;10(6):1158. doi:10.3390/jcm10061158
11. Voiță-Mekereș F, Delcea C, Buhaș CL, Ciocan V. Novichok toxicology: a review study. *Arch Pharm Pract.* 2023;14(3):62-6.
12. Ali F, Sweeney DA. No one likes a stick up their nose: making the case for saliva-based testing for coronavirus disease 2019 (COVID-19). *Clin Infect Dis.* 2021;72(9):e357-8. doi:10.1093/cid/ciaa1314
13. Ibrahim N, Delaunay-Moisin A, Hill C, Le Teuff G, Rupprecht JF, Thuret JY, et al. Screening for SARS-CoV-2 by RT-PCR: Saliva or nasopharyngeal swab? Rapid review and meta-analysis. *PLoS One.* 2021;16(6):e0253007. doi:10.1371/journal.pone.0253007
14. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. *Int J Antimicrob Agents.* 2020;55(5):105951. doi:10.1016/j.ijantimicag.2020.105951
15. Khiabani K, Amirzade-Iranaq MH. Are saliva and deep throat sputum as reliable as common respiratory specimens for SARS-CoV-2 detection? A systematic review and meta-analysis. *Am J Infect Control.* 2021;49(9):1165-76. doi:10.1016/j.ajic.2021.03.008
16. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a systematic review and meta-analysis. *J Clin Microbiol.* 2021;59(5):e02881-20. doi:10.1128/JCM.02881-20
17. Rus M, Matei R, Sandu ML, Delcea C, Siserman C. Emotional distress and coping strategies of health care workers during COVID-19 pandemic. *Rom J Leg Med.* 2020;28:442-50.
18. Delcea C, Siserman C. The emotional impact of Covid-19 on forensic staff. *Rom J Leg Med.* 2021;29(1):142-6.
19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372:n71. doi:10.1136/bmj.n71
20. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med.* 2011;155(8):529-36. doi:10.7326/0003-4819-155-8-201110180-00009
21. Bristol UO. QUADAS-2. Bristol medical school: population health sciences. 2020. Retrieved from: <https://www.bristol.ac.uk/population-health-sciences/projects/quadas/quadas-2/> (accessed May 7th 2021).
22. Altawalah H, AlHuraish F, Alkandari WA, Ezzikouri S. Saliva specimens for detection of severe acute respiratory syndrome coronavirus 2 in Kuwait: a cross-sectional study. *J Clin Virol.* 2020;132:104652. doi:10.1016/j.jcv.2020.104652
23. Amendola A, Sberna G, Lalle E, Colavita F, Castilletti C, Menchinelli G, et al. Saliva is a valid alternative to nasopharyngeal swab in chemiluminescence-based assay for detection of SARS-CoV-2 antigen. *J Clin Med.* 2021;10(7):1471. doi:10.3390/jcm10071471
24. Ana Laura GO, Abraham Josué NR, Briceida LM, Israel PO, Tania AF, Nancy MR, et al. Sensitivity of the molecular test in saliva for detection of COVID-19 in pediatric patients with concurrent conditions. *Front Pediatr.* 2021;9:642781. doi:10.3389/fped.2021.642781
25. Babady NE, McMillen T, Jani K, Viale A, Robilotti EV, Aslam A, et al. Performance of severe acute respiratory syndrome coronavirus 2 real-time RT-PCR tests on oral rinses and saliva samples. *J Mol Diagn.* 2021;23(1):3-9. doi:10.1016/j.jmoldx.2020.10.018
26. Braz-Silva PH, Mamana AC, Romano CM, Felix AC, de Paula AV, Ferreira NE, et al. Performance of at-home self-collected saliva and nasal-oropharyngeal swabs in the surveillance of COVID-19. *J Oral Microbiol.* 2020;13(1):1858002. doi:10.1080/20002297.2020.1858002
27. Griesemer SB, Van Slyke G, Ehrbar D, Strle K, Yildirim T, Centurioni DA, et al. Evaluation of specimen types and saliva stabilization solutions for SARS-CoV-2 testing. *J Clin Microbiol.* 2021;59(5):e01418-20. doi:10.1128/JCM.01418-20
28. Herrera LA, Hidalgo-Miranda A, Reynoso-Noverón N, Meneses-García AA, Mendoza-Vargas A, Reyes-Grajeda JP, et al. Saliva is a reliable and accessible source for the detection of SARS-CoV-2. *Int J Infect Dis.* 2021;105:83-90. doi:10.1016/j.ijid.2021.02.009
29. Jamal AJ, Mozafarihashjin M, Coomes E, Powis J, Li AX, Paterson A, et al. Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2. *Clin Infect Dis.* 2021;72(6):1064-6. doi:10.1093/cid/ciaa848
30. Jamal AJ, Mozafarihashjin M, Coomes E, Anceva-Sami S, Barati S, Crawl G, et al. Sensitivity of

- midturbinate versus nasopharyngeal swabs for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Infect Control Hosp Epidemiol.* 2021;42(8):1001-3. doi:10.1017/ice.2020.1326
31. Manabe YC, Reuland C, Yu T, Azamfirei R, Hardick JP, Church T, et al. Self-collected oral fluid saliva is insensitive compared with nasal-oropharyngeal swabs in the detection of severe acute respiratory syndrome coronavirus 2 in outpatients. *Open Forum Infect Dis.* 2020;8(2):ofaa648. doi:10.1093/ofid/ofaa648
 32. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G, Suksuwan W, et al. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. *Clin Microbiol Infect.* 2021;27(2):285. doi:10.1016/j.cmi.2020.05.001
 33. Plantamura J, Bousquet A, Otto MP, Bigaillon C, Legland AM, Delacour H, et al. Performances, feasibility and acceptability of nasopharyngeal swab, saliva and oral-self sampling swab for the detection of severe acute respiratory syndrome coronavirus 2. *Eur J Clin Microbiol Infect Dis.* 2021;40(10):2191-8. doi:10.1007/s10096-021-04269-4
 34. Procop GW, Shrestha NK, Vogel S, Van Sickle K, Harrington S, Rhoads DD, et al. A direct comparison of enhanced saliva to nasopharyngeal swab for the detection of SARS-CoV-2 in symptomatic patients. *J Clin Microbiol.* 2020;58(11):e01946-20. doi:10.1128/JCM.01946-20
 35. Rao M, Rashid FA, Sabri FSAH, Jamil NN, Seradja V, Abdullah NA, et al. COVID-19 screening test by using random oropharyngeal saliva. *J Med Virol.* 2021;93(4):2461-6. doi:10.1002/jmv.26773
 36. Senok A, Alsuwaidi H, Atrah Y, Al Ayedi O, Al Zahid J, Han A, et al. Saliva as an alternative specimen for molecular COVID-19 testing in community settings and population-based screening. *Infect Drug Resist.* 2020;13:3393-9. doi:10.2147/IDR.S275152
 37. Sun Q, Li J, Ren H, Pastor L, Loginova Y, Madej R, et al. Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test. *PLoS One.* 2021;16(2):e0243183. doi:10.1371/journal.pone.0243183
 38. Sutjipto S, Lee PH, Tay JY, Mendis SM, Abdad MY, Marimuthu K, et al. The effect of sample site, illness duration, and the presence of pneumonia on the detection of SARS-CoV-2 by real-time reverse transcription PCR. *Open Forum Infect Dis.* 2020;7(9):ofaa335. doi:10.1093/ofid/ofaa335
 39. Vaz SN, Santana DS, Netto EM, Pedroso C, Wang WK, Santos FDA, et al. Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection. *Braz J Infect Dis.* 2020;24(5):422-7. doi:10.1016/j.bjid.2020.08.001
 40. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, et al. Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients. *Int J Infect Dis.* 2020;99:397-402. doi:10.1016/j.ijid.2020.08.029
 41. Toptan T, Eckermann L, Pfeiffer AE, Hoehl S, Ciesek S, Drosten C, et al. Evaluation of a SARS-CoV-2 rapid antigen test: potential to help reduce community spread? *J Clin Virol.* 2021;135:104713. doi:10.1016/j.jcv.2020.104713
 42. Chansaenroj J, Yorsaeng R, Posuwan N, Puenpa J, Sudhinaraset N, Chirathaworn C, et al. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients. *Virol J.* 2021;18(1):52. doi:10.1186/s12985-021-01530-2
 43. Dou X, Wang E, Hu J, Zong Z, Jiang R, Wang M, et al. Comparison of three automatic chemiluminescent immunoassays for monitoring dynamic profile of SARS-CoV-2 IgG and IgM. *J Clin Lab Anal.* 2021;35(1):e23681. doi:10.1002/jcla.23681
 44. Kim D, Lee J, Bal J, Chong CK, Lee JH, Park H. Clinical evaluation of an immunochromatographic-based IgM/IgG antibody assay (GenBody™ COVI040) for detection of antibody seroconversion in patients with SARS-CoV-2 infection. *Diagnostics (Basel).* 2021;11(3):537. doi:10.3390/diagnostics11030537
 45. Pérez-García F, Pérez-Tanoira R, Romanyk J, Arroyo T, Gómez-Herruz P, Cuadros-González J. Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: a prospective single-center study. *J Clin Virol.* 2020;129:104473. doi:10.1016/j.jcv.2020.104473
 46. Plebani M, Parčina M, Bechri I, Zehender G, Terkeš V, Abdel Hafith B, et al. Performance of the COVID19SEROspeed IgM/IgG rapid test, an immunochromatographic assay for the diagnosis of SARS-CoV-2 infection: a multicenter European

- study. *J Clin Microbiol.* 2021;59(2):e02240-20. doi:10.1128/JCM.02240-20
47. Van Elslande J, Houben E, Depypere M, Brackenier A, Desmet S, André E, et al. Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. *Clin Microbiol Infect.* 2020;26(8):1082-7. doi:10.1016/j.cmi.2020.05.023
48. Wu JL, Tseng WP, Lin CH, Lee TF, Chung MY, Huang CH, et al. Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2. *J Infect.* 2020;81(3):435-42. doi:10.1016/j.jinf.2020.06.023
49. Bwire GM, Majigo MV, Njiro BJ, Mawazo A. Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: a systematic review and meta-analysis. *J Med Virol.* 2021;93(2):719-25. doi:10.1002/jmv.26349
50. Gopaul R, Davis J, Gangai L, Goetz L. Practical diagnostic accuracy of nasopharyngeal swab testing for novel coronavirus disease 2019 (COVID-19). *West J Emerg Med.* 2020;21(6):1-4. doi:10.5811/westjem.2020.8.48420
51. Evans LK, Shinagawa A, Sutton S, Calvo L. COVID-19 drive-through point of screening and testing (POST) system: a safe, efficient, and adaptable model for nasopharyngeal swab collection. *Disaster Med Public Health Prep.* 2022;16(1):194-200. doi:10.1017/dmp.2020.313
52. Sangal RB, Peaper DR, Rothenberg C, Fadlallah H, Mobolaji-Lawal M, Landry ML, et al. Real-world assessment of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) nasopharyngeal swab testing in a region with a high burden of coronavirus disease 2019 (COVID-19). *Infect Control Hosp Epidemiol.* 2022;43(8):1051-3. doi:10.1017/ice.2021.153
53. Ghandaali A, Ardestani MM, Hadi S, Nejatbakhsh F, Hadi V, Kazemi-Galougahi MH, et al. Effects of almond porridge, grape extract, and pea syrup on fatigue severity of patients with COVID-19. *Clin Cancer Investig J.* 2023;12(3):32-9.
54. Clementi N, Ferrarese R, Tonelli M, Amato V, Racca S, Locatelli M, et al. Lower nasopharyngeal viral load during the latest phase of COVID-19 pandemic in a northern Italy university hospital. *Clin Chem Lab Med.* 2020;58(9):1573-7. doi:10.1515/cclm-2020-0815
55. Liu R, Yi S, Zhang J, Lv Z, Zhu C, Zhang Y. Viral load dynamics in sputum and nasopharyngeal swab in patients with COVID-19. *J Dent Res.* 2020;99(11):1239-44. doi:10.1177/0022034520946251
56. Esposito S, Marchetti F, Lanari M, Caramelli F, De Fanti A, Vergine G, et al. COVID-19 management in the pediatric age: consensus document of the COVID-19 working group in paediatrics of the emilia-romagna region (RE-CO-Ped), Italy. *Int J Environ Res Public Health.* 2021;18(8):3919. doi:10.3390/ijerph18083919
57. Palmas G, Moriondo M, Trapani S, Ricci S, Calistri E, Pisano L, et al. Nasal swab as preferred clinical specimen for COVID-19 testing in children. *Pediatr Infect Dis J.* 2020;39(9):e267-70. doi:10.1097/INF.0000000000002812
58. Hoang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID-19 in 7780 pediatric patients: a systematic review. *EclinicalMedicine.* 2020;24:100433. doi:10.1016/j.eclinm.2020.100433
59. Yamamoto L, Santos EHD, Pinto LS, Rocha MC, Kanunfre KA, Vallada MG, et al. SARS-CoV-2 infections with emphasis on pediatric patients: a narrative review. *Rev Inst Med Trop Sao Paulo.* 2020;62:e65. doi:10.1590/S1678-9946202062065
60. Capecchi E, Di Pietro GM, Luconi E; Testing Pediatric COVID-19 (TPC-19). Is nasopharyngeal swab comparable with nasopharyngeal aspirate to detect SARS-CoV-2 in children? *Pediatr Infect Dis J.* 2020;39(9):e288-9. doi:10.1097/INF.0000000000002824
61. Azar A, Wessell DE, Janus JR, Simon LV. Fractured aluminum nasopharyngeal swab during drive-through testing for COVID-19: radiographic detection of a retained foreign body. *Skeletal Radiol.* 2020;49(11):1873-7. doi:10.1007/s00256-020-03582-x
62. Gaffuri M, Capaccio P, Torretta S, Daga M, Zuccotti GV, Pignataro L. An unusual retained choanal foreign body: a possible complication of COVID-19 testing with nasopharyngeal swab. *Ear Nose Throat J.* 2023;102(3):NP136-9. doi:10.1177/0145561321993933
63. De Luca L, Maltoni S. Is naso-pharyngeal swab always safe for SARS-CoV-2 testing? An unusual, accidental foreign body swallowing. *Clin J Gastroenterol.* 2021;14(1):44-7. doi:10.1007/s12328-020-01236-y
64. Stevens MN, Lin GT, Tittman SM, Motz KM. SARS-CoV-2 Nasopharyngeal swab as a foreign body: a case report. *Ear Nose Throat J.* 2023;102(3):NP133-5. doi:10.1177/0145561321996836

65. Clark JH, Pang S, Naclerio RM, Kashima M. Complications of nasal SARS-CoV-2 testing: a review. *J Investig Med.* 2021;69(8):1399-403. doi:10.1136/jim-2021-001962
66. Gupta K, Bellino PM, Charness ME. Adverse effects of nasopharyngeal swabs: three-dimensional printed versus commercial swabs. *Infect Control Hosp Epidemiol.* 2021;42(5):641-2. doi:10.1017/ice.2020.297
67. Mughal Z, Luff E, Okonkwo O, Hall CEJ. Test, test, test - a complication of testing for coronavirus disease 2019 with nasal swabs. *J Laryngol Otol.* 2020;134(7):646-9. doi:10.1017/S0022215120001425
68. Edouard S, Colson P, Melenotte C, Di Pinto F, Thomas L, La Scola B, et al. Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France. *Eur J Clin Microbiol Infect Dis.* 2021;40(2):361-71. doi:10.1007/s10096-020-04104-2
69. Iruzubieta P, Fernández-Lanas T, Rasines L, Cayon L, Álvarez-Cancelo A, Santos-Laso A, et al. Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. *Sci Rep.* 2021;11(1):9819. doi:10.1038/s41598-021-89236-x
70. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Sci Immunol.* 2020;5(52):eabe5511. doi:10.1126/sciimmunol.abe5511
71. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et al. COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva. *J Clin Microbiol.* 2020;59(1):e02204-20. doi:10.1128/JCM.02204-20
72. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis.* 2020;20(5):565-74. doi:10.1016/S1473-3099(20)30196-1
73. Marklund E, Leach S, Axelsson H, Nyström K, Norder H, Bemark M, et al. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. *PLoS One.* 2020;15(10):e0241104. doi:10.1371/journal.pone.0241104
74. Mojsak D, Dębczyński M, Kuklińska B, Mróz RM. Ewing's sarcoma in a 58-year-old man: oncological diagnosis in the time of COVID-19. *Clin Cancer Investig J.* 2022;11(1):1-4.
75. Moura DTH, McCarty TR, Ribeiro IB, Funari MP, Oliveira PVAG, Miranda Neto AA, et al. Diagnostic characteristics of serological-based COVID-19 testing: a systematic review and meta-analysis. *Clinics (Sao Paulo).* 2020;75:e2212. doi:10.6061/clinics/2020/e2212
76. Li L, Tan C, Zeng J, Luo C, Hu S, Peng Y, et al. Analysis of viral load in different specimen types and serum antibody levels of COVID-19 patients. *J Transl Med.* 2021;19(1):30. doi:10.1186/s12967-020-02693-2
77. Zainol Rashid Z, Othman SN, Abdul Samat MN, Ali UK, Wong KK. Diagnostic performance of COVID-19 serology assays. *Malays J Pathol.* 2020;42(1):13-21.
78. Radu CC, Delcea C, Plesa A, Rad D. Transforming perceptions of drug consumption among youth through a cognitive-social-medico-legal educational approach. *Pharmacophore.* 2023;14(4):50-6.
79. Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, et al. Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques. *J Virol.* 2011;85(8):4025-30. doi:10.1128/JVI.02292-10
80. Baghizadeh Fini M. Oral saliva and COVID-19. *Oral Oncol.* 2020;108:104821. doi:10.1016/j.oraloncology.2020.104821
81. Sabino-Silva R, Jardim ACG, Siqueira WL. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. *Clin Oral Investig.* 2020;24(4):1619-21. doi:10.1007/s00784-020-03248-x
82. Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary glands: potential reservoirs for COVID-19 asymptomatic infection. *J Dent Res.* 2020;99(8):989. doi:10.1177/0022034520918518
83. Chen JH, Yip CC, Poon RW, Chan KH, Cheng VC, Hung IF, et al. Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. *Emerg Microbes Infect.* 2020;9(1):1356-9. doi:10.1080/22221751.2020.1775133
84. McCormick-Baw C, Morgan K, Gaffney D, Cazares Y, Jaworski K, Byrd A, et al. Saliva as an alternate specimen source for detection of SARS-CoV-2 in symptomatic patients using cepheid xpert xpress SARS-CoV-2. *J Clin Microbiol.* 2020;58(8):e01109-20. doi:10.1128/JCM.01109-20

85. Iwasaki S, Fujisawa S, Nakakubo S, Kamada K, Yamashita Y, Fukumoto T, et al. Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. *J Infect.* 2020;81(2):e145-7. doi:10.1016/j.jinf.2020.05.071
86. Wong SCY, Tse H, Siu HK, Kwong TS, Chu MY, Yau FYS, et al. Posterior oropharyngeal saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* 2020;71(11):2939-46. doi:10.1093/cid/ciaa797
87. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, et al. Saliva is a reliable tool to detect SARS-CoV-2. *J Infect.* 2020;81(1):e45-50. doi:10.1016/j.jinf.2020.04.005
88. Van Vinh Chau N, Lam VT, Dung NT, Yen LM, Minh NNQ, Hung LM, et al. The natural history and transmission potential of asymptomatic severe acute respiratory syndrome coronavirus 2 infection. *Clin Infect Dis.* 2020;71(10):2679-87. doi:10.1093/cid/ciaa711
89. Miguères M, Mengelle C, Dimeglio C, Didier A, Alvarez M, Delobel P, et al. Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers. *J Clin Virol.* 2020;130:104580. doi:10.1016/j.jcv.2020.104580
90. Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q. Saliva: potential diagnostic value and transmission of 2019-nCoV. *Int J Oral Sci.* 2020;12(1):11. doi:10.1038/s41368-020-0080-z
91. Hari Krishnan P. Saliva as a potential diagnostic specimen for COVID-19 testing. *J Craniofac Surg.* 2022;31(6):e653-5. doi:10.1097/SCS.00000000000006724
92. AlOsaimi MM, AlSubaheen AM, Jameel TS, AlSalamah RA, AlAnzi DN, AlOushan NA, et al. Advanced diagnostic methods for salivary glands diseases: a narrative review study. *Clin Cancer Investig J.* 2023;12(4):19-26.
93. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. *N Engl J Med.* 2020;383(13):1283-6. doi:10.1056/NEJMc2016359
94. Hung KF, Sun YC, Chen BH, Lo JF, Cheng CM, Chen CY, et al. New COVID-19 saliva-based test: How good is it compared with the current nasopharyngeal or throat swab test? *J Chin Med Assoc.* 2020;83(10):891-4. doi:10.1097/JCMA.0000000000000396
95. Sakanashi D, Asai N, Nakamura A, Miyazaki N, Kawamoto Y, Ohno T, et al. Comparative evaluation of nasopharyngeal swab and saliva specimens for the molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19. *J Infect Chemother.* 2021;27(1):126-9. doi:10.1016/j.jiac.2020.09.027
96. Azzi L, Maurino V, Baj A, Dani M, d'Aiuto A, Fasano M, et al. Diagnostic salivary tests for SARS-CoV-2. *J Dent Res.* 2021;100(2):115-23. doi:10.1177/0022034520969670
97. Chu AW, Chan WM, Ip JD, Yip CC, Chan JF, Yuen KY, et al. Evaluation of simple nucleic acid extraction methods for the detection of SARS-CoV-2 in nasopharyngeal and saliva specimens during global shortage of extraction kits. *J Clin Virol.* 2020;129:104519. doi:10.1016/j.jcv.2020.104519
98. Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The sensitivity and costs of testing for SARS-CoV-2 infection with saliva versus nasopharyngeal swabs: a systematic review and meta-analysis. *Ann Intern Med.* 2021;174(4):501-10. doi:10.7326/M20-6569
99. Yoon JG, Yoon J, Song JY, Yoon SY, Lim CS, Seong H, et al. Clinical significance of a high SARS-CoV-2 viral load in the saliva. *J Korean Med Sci.* 2020;35(20):e195. doi:10.3346/jkms.2020.35.e195
100. Yokota I, Shane PY, Okada K, Unoki Y, Yang Y, Inao T, et al. Mass screening of asymptomatic persons for severe acute respiratory syndrome coronavirus 2 using saliva. *Clin Infect Dis.* 2021;73(3):e559-65. doi:10.1093/cid/ciaa1388
101. Barat B, Das S, De Giorgi V, Henderson DK, Kopka S, Lau AF, et al. Pooled saliva specimens for SARS-CoV-2 testing. *J Clin Microbiol.* 2021;59(3):e02486-20. doi:10.1128/JCM.02486-20
102. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, et al. Self-collected anterior nasal and saliva specimens versus health care worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2. *J Clin Microbiol.* 2020;58(11):e01824-20. doi:10.1128/JCM.01824-20
103. Sahajpal NS, Mondal AK, Njau A, Ananth S, Ghamande S, Hegde M, et al. COVID-19 screening in a healthcare or community setting: complexity of saliva as a specimen for PCR-based testing. *Future Med Chem.* 2021;13(1):9-12. doi:10.4155/fmc-2020-0255

104. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, et al. Clinical evaluation of self-collected saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription-loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19. *J Clin Microbiol.* 2020;58(9):e01438-20. doi:10.1128/JCM.01438-20
105. Henrique Braz-Silva P, Pallos D, Giannecchini S, To KK. SARS-CoV-2: What can saliva tell us? *Oral Dis.* 2021;27 Suppl 3(Suppl 3):746-7. doi:10.1111/odi.13365